Contentious Issues in Gout Management: The Story so Far

References

• Brown R Manafort suffering depression, anxiety, gout in jail: lawyers. [cited February 17, 2021]. Available from: https://nypost.com/2019/01/08/manafort-suffering-depression-anxiety-gout-in-jail-lawyers/. Accessed April 2, 2021.
   Google Scholar
• Mishan L Once the disease of gluttonous aristocrats, gout is now tormenting the masses; 2020 [cited February 17, 2021]. Available from: https://www.nytimes.com/2020/11/13/t-magazine/gout-tormenting-masses.html. Accessed April 2, 2021.
   Google Scholar
• Schlesinger N. Treatment of acute gout. Rheum Dis Clin North Am. 2014;40(2):329–341. doi:10.1016/j.rdc.2014.01.008
   Web of Science ®Google Scholar
• Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8 Suppl 1(Suppl1):S3. doi:10.1186/ar1908
   Web of Science ®Google Scholar
• Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–241. doi:10.1038/nature04516
   PubMed Web of Science ®Google Scholar
• Schlesinger N. Difficult-to-treat gouty arthritis A disease warranting better management. Drugs. 2011;71(11):1413–1439. doi:10.2165/11592290-000000000-00000
   PubMed Web of Science ®Google Scholar
• Rainer TH, Cheng CH, Janssens HJEM, et al. Oral prednisolone in the treatment of acute Gout: a Pragmatic, Multicenter, Double-Blind, Randomized Trial. Ann Intern Med. 2016;164(7):464–471. doi:10.7326/M14-2070
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–1068. doi:10.1002/art.27327
   PubMed Web of Science ®Google Scholar
• Schlesinger N. Anti-interleukin-1 therapy in the management of Gout. Curr Rheumatol Rep. 2014;16(2):398. doi:10.1007/s11926-013-0398-z
   PubMed Web of Science ®Google Scholar
• Saag K, So A, Khanna P, et al. THU0409 A randomized, Phase 2 study evaluating the efficacy and safety of ANAKINRA in difficult-to-treat acute Gouty Arthritis: THE Anago Study. Ann Rheum Dis. 2020;79(Suppl 1):442. doi:10.1136/annrheumdis-2020-eular.3766
   Web of Science ®Google Scholar
• Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–1848. doi:10.1136/annrheumdis-2011-200908
   PubMed Web of Science ®Google Scholar
• FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744–760. doi:10.1002/acr.24180
   PubMed Web of Science ®Google Scholar
• Taylor TH, Mecchella JN, Larson RJ, et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 2012;125(11):1126–1134. e7. doi:10.1016/j.amjmed.2012.05.025
   PubMed Web of Science ®Google Scholar
• Feng X, Li Y, Gao W. Significance of the initiation time of urate-lowering therapy in gout patients: a retrospective research. Joint Bone Spine. 2015;82(6):428–431. doi:10.1016/j.jbspin.2015.02.021
   Web of Science ®Google Scholar
• Schlesinger N, Brunetti L. Beyond urate lowering: analgesic and anti-inflammatory properties of allopurinol. Semin Arthritis Rheum. 2020;50(3):444–450. doi:10.1016/j.semarthrit.2019.11.009
   PubMed Web of Science ®Google Scholar
• De Miguel E, Puig JG, Castillo C, et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis. 2012;71(1):157–158. doi:10.1136/ard.2011.154997
   PubMed Web of Science ®Google Scholar
• Dalbeth N, House ME, Aati O, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann Rheum Dis. 2015;74(5):908–911. doi:10.1136/annrheumdis-2014-206397
   PubMed Web of Science ®Google Scholar
• Andrés M, Quintanilla M-A, Sivera F, et al. Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an Exploratory Study. Arthritis Rheumatol. 2016;68(6):1531–1539. doi:10.1002/art.39581
   Web of Science ®Google Scholar
• Abhishek A, Courtney P, Jenkins W, et al. Brief report: monosodium urate monohydrate crystal deposits are common in asymptomatic sons of patients with Gout: the Sons of Gout Study. Arthritis Rheumatol. 2018;70(11):1847–1852. doi:10.1002/art.40572
   Web of Science ®Google Scholar
• Hill EM, Sky K, Sit M, et al. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol. 2015;21(3):120–125. doi:10.1097/RHU.0000000000000235
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461. doi:10.1056/NEJMoa050373
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with Gout. N Engl J Med. 2018;378(13):1200–1210. doi:10.1056/NEJMoa1710895
   PubMed Web of Science ®Google Scholar
• Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: update on efficacy and safety. Semin Arthritis Rheum. 2020;50(3s):S31–S38. doi:10.1016/j.semarthrit.2020.04.011
   PubMed Web of Science ®Google Scholar
• Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745–1757. doi:10.1016/S0140-6736(20)32234-0
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545–549. doi:10.1136/ard.57.9.545
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, Actively Controlled Study. J Clin Rheumatol. 1999;5(2):49–55. doi:10.1097/00124743-199904000-00003
   PubMed Web of Science ®Google Scholar
• Hanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai. 2002;85(Suppl 1):S40–7.
   PubMedGoogle Scholar
• Boss GR, Seegmiller JE. Hyperuricemia and gout: Classification, complications and management. N Engl J Med. 1979;300(26):1459–1468. doi:10.1056/NEJM197906283002604
   PubMed Web of Science ®Google Scholar
• Ravera R. Il benbromarone nel trattamento delle iperuricemia. [Benzbromarone in the treatment of hyperuricemias]. Minerva Med. 1975;66(17):783–800. Italian.
   Google Scholar
• Didier M, Olmer M. Effet hypo-uricémiant de la benzbromarone en particulier dans l'insuffisance rénale. [Hypouricemic effect of benzbromarone especially in kidney failure]. Sem Hop. 1978;54(9–12):463–465. French.
   Google Scholar
• Kumar S, Ng J, Gow P. Benzbromarone therapy in management of refractory gout. N Z Med J. 2005;118(1217):U1528.
   Google Scholar
• Masbernard A, Giudicelli CP. Ten years’ experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J. 1981;59(20):701–706.
   Web of Science ®Google Scholar
• van der Klauw MM, Houtman PM, Stricker BHC, et al. Hepatic injury caused by benzbromarone. J Hepatol. 1994;20(3):376–379. doi:10.1016/S0168-8278(94)80011-1
   PubMed Web of Science ®Google Scholar
• Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol. 2000;32(5):874. doi:10.1016/S0168-8278(00)80263-9
   Web of Science ®Google Scholar
• Suzuki T, Suzuki T, Kimura M, et al. [A case of fulminant hepatitis, possibly caused by benzbromarone]. Nihon Shokakibyo Gakkai Zasshi. 2001;98(4):421–425. Japanese.
   Google Scholar
• Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol. 2002;17(5):625–626. doi:10.1046/j.1440-1746.2002.02692.x
   Web of Science ®Google Scholar
• Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643–665. doi:10.2165/00002018-200831080-00002
   PubMed Web of Science ®Google Scholar
• Waller A, Jordan KM. Use of febuxostat in the management of gout in the United Kingdom. Ther Adv Musculoskelet Dis. 2017;9(2):55–64. doi:10.1177/1759720X16682010
   Web of Science ®Google Scholar
• Stamp LK, Chapman PT, Barclay M, et al. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. Arthritis Res Ther. 2017;19(1):283. doi:10.1186/s13075-017-1491-x
   Web of Science ®Google Scholar
• Sakai Y, Otsuka T, Ohno D, et al. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease. Ren Fail. 2014;36(2):225–231. doi:10.3109/0886022X.2013.844622
   Web of Science ®Google Scholar
• Liu X, Wang H, Ma R, et al. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3–5. Clin Exp Nephrol. 2019;23(3):362–370. doi:10.1007/s10157-018-1652-5
   PubMed Web of Science ®Google Scholar
• Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a Randomized Trial. Am J Kidney Dis. 2018;72(6):798–810. doi:10.1053/j.ajkd.2018.06.028
   PubMed Web of Science ®Google Scholar
• Kim S, Kim H-J, Ahn H-S, et al. Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: a systematic review and meta-analysis. Kidney Res Clin Pract. 2017;36(3):274–281. doi:10.23876/j.krcp.2017.36.3.274
   Web of Science ®Google Scholar
• Singh JA, Cleveland JD. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Ann Rheum Dis. 2017;76(10):1669–1678. doi:10.1136/annrheumdis-2017-211210
   Web of Science ®Google Scholar
• Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–325. doi:10.1002/art.20405
   PubMed Web of Science ®Google Scholar
• Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12(2):61–65. doi:10.1097/01.rhu.0000209882.50228.9f
   PubMed Web of Science ®Google Scholar
• Stamp L, Morillon MB, Taylor WJ, et al. Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regression analysis. Semin Arthritis Rheum. 2018;48(2):293–301. doi:10.1016/j.semarthrit.2018.02.009
   Web of Science ®Google Scholar
• Yamanaka H, Tamaki S, Ide Y, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2):270–276. doi:10.1136/annrheumdis-2017-211574
   PubMed Web of Science ®Google Scholar
• Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392(10156):1403–1412. doi:10.1016/S0140-6736(18)32158-5
   PubMed Web of Science ®Google Scholar
• Schlesinger N, Etzel CJ, Greenberg J, et al. Gout prophylaxis evaluated according to the 2012 American College of Rheumatology Guidelines: analysis from the CORRONA Gout Registry. J Rheumatol. 2016;43(5):924–930. doi:10.3899/jrheum.150345
   Web of Science ®Google Scholar
• Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155–165. doi:10.1016/j.semarthrit.2012.03.010
   PubMed Web of Science ®Google Scholar
• Maes ML, Saseen, JJ, Wright G, et al. Utilization of acute gout prophylaxis in the real world: a retrospective database cohort analysis. Clin Rheumatol. 2021;40:1017–1026.
   Web of Science ®Google Scholar
• Tai V, Merriman TR, Dalbeth N. Genetic advances in gout: potential applications in clinical practice. Curr Opin Rheumatol. 2019;31(2):144–151. doi:10.1097/BOR.0000000000000571
   Web of Science ®Google Scholar
• Dehghan A, Köttgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372(9654):1953–1961. doi:10.1016/S0140-6736(08)61343-4
   PubMed Web of Science ®Google Scholar
• Matsuo H, Yamamoto K, Nakaoka H, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis. 2016;75(4):652–659. doi:10.1136/annrheumdis-2014-206191
   PubMed Web of Science ®Google Scholar
• Dong Z, Guo S, Yang Y, et al. Association between ABCG2 Q141K polymorphism and gout risk affected by ethnicity and gender: a systematic review and meta-analysis. Int J Rheum Dis. 2015;18(4):382–391. doi:10.1111/1756-185X.12519
   PubMed Web of Science ®Google Scholar
• González-Galarza FF, Takeshita LC, Santos EM, et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 2015;43(D1):D784–8. doi:10.1093/nar/gku1166
   PubMed Web of Science ®Google Scholar
• Jutkowitz E, Dubreuil M, Lu N, et al. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017;46(5):594–600. doi:10.1016/j.semarthrit.2016.10.009
   PubMed Web of Science ®Google Scholar
• Ke C-H, Chung W-H, Wen Y-H, et al. Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol. 2017;44(6):835–843. doi:10.3899/jrheum.151476
   PubMed Web of Science ®Google Scholar
• Park D-J, Kang J-H, Lee J-W, et al. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis Care Res (Hoboken). 2015;67(2):280–287. doi:10.1002/acr.22409
   Web of Science ®Google Scholar
• Chong HY, Lim YH, Prawjaeng J, et al. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. Pharmacogenet Genomics. 2018;28(2):56–67. doi:10.1097/FPC.0000000000000319
   PubMed Web of Science ®Google Scholar
• Dong D, Tan-Koi W-C, Teng GG, et al. Cost–effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. Pharmacogenomics. 2015;16(16):1781–1793. doi:10.2217/pgs.15.125
   Web of Science ®Google Scholar
• Plumpton CO, Alfirevic A, Pirmohamed M, et al. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology (Oxford). 2017;56(10):1729–1739. doi:10.1093/rheumatology/kex253
   PubMed Web of Science ®Google Scholar
• Singh JA. Patient perspectives in gout: a review. Curr Opin Rheumatol. 2019;31(2):159–166. doi:10.1097/BOR.0000000000000583
   PubMed Web of Science ®Google Scholar
• Singh JA. Gout and sexual function: patient perspective of how gout affects personal relationships and intimacy. BMC Rheumatol. 2019;3(1):8. doi:10.1186/s41927-019-0056-9
   PubMedGoogle Scholar
• Singh JA. The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther. 2014;16(3):R132. doi:10.1186/ar4589
   PubMed Web of Science ®Google Scholar
• Singh JA, Edwards NL. Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey. Ther Adv Musculoskelet Dis. 2020;12:1759720x20966124. doi:10.1177/1759720X20966124
   Web of Science ®Google Scholar
• Singh JA, Neogi T, FitzGerald JD. Patient perspectives on gout and gout treatments: a patient panel discussion that informed the 2020 American College of Rheumatology Treatment Guideline. ACR Open Rheumatol. 2020;2(12):725–733. doi:10.1002/acr2.11199
   Google Scholar
• Hartung EF. Colchicine and its analogs in gout: a brief review. Arthritis Rheum. 1961;4(1):18–26. doi:10.1002/art.1780040103
   Web of Science ®Google Scholar
• Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458–1464. doi:10.3899/jrheum.111533
   PubMed Web of Science ®Google Scholar
• Solomon DH, Liu -C-C, Kuo I-H, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674–1679. doi:10.1136/annrheumdis-2015-207984
   Web of Science ®Google Scholar
• Alayli G, Cengiz K, Cantürk F, et al. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39(7–8):1358–1361. doi:10.1345/aph.1E593
   PubMed Web of Science ®Google Scholar
• Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505. doi:10.1056/NEJMoa1912388
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21(6):1291–1298. doi:10.1111/dom.13670
   PubMed Web of Science ®Google Scholar
• Fralick M, Chen SK, Patorno E, et al. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with Type 2 diabetes: a Population-Based Cohort Study. Ann Intern Med. 2020;172(3):186–194. doi:10.7326/M19-2610
   PubMed Web of Science ®Google Scholar
• Qaseem A, Harris RP, Forciea MA. Management of acute and recurrent Gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58–68. doi:10.7326/M16-0570
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. doi:10.1136/annrheumdis-2016-209707
   PubMed Web of Science ®Google Scholar